Palo Alto, Calif.-based Cognoa Inc. received breakthrough device designations from the U.S. FDA for its digital diagnostic and digital therapeutic devices for autism. Cognoa's digital precision health platform weds machine learning and predictive analytics to parental inputs and diagnostic data and responses to therapeutics to create more personalized care. The single platform aims to help clinicians to come to accurate diagnostic and therapeutic decisions faster and modify treatments.